Acadia Pharmaceuticals ACAD Investment Proceeds
Investment Proceeds at other companies
Other financials
Where this comes from
Reported directly by Acadia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.
The official record: Acadia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Acadia Pharmaceuticals's investment proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Acadia Pharmaceuticals's investment proceeds?
- Acadia Pharmaceuticals (ACAD) reported investment proceeds of $86.5M in Q1 2026.
- How has Acadia Pharmaceuticals's investment proceeds changed year-over-year?
- Acadia Pharmaceuticals's investment proceeds decreased by 33.9% year-over-year, from $130.8M to $86.5M.
- What is the long-term trend for Acadia Pharmaceuticals's investment proceeds?
- Over 4 years (2021 to 2025), Acadia Pharmaceuticals's investment proceeds has grown at a 3.9% compound annual growth rate (CAGR), from $422.82M to $493.53M.
- What does investment proceeds mean?
- Cash received from sales, maturities, and redemptions of investment securities across all categories.